Skip to main content
Journal ArticleOPEN ACCESS

EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with multiple brain metastases

  • Jiang T
  • Zhou C
Annals of Oncology (2019) 30 ii69-ii70
DOI: 10.1093/annonc/mdz068
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

… 22.4 m, P < 0.001). Different types of EGFR-TKIs showed comparable efficacy when combined with bevacizumab. However, erlotinib was associated with a significantly longer iPFS but similar sPFS and OS when compared with gefitinb and icotinib mono- therapy …

Cite

CITATION STYLE

APA

Jiang, T., & Zhou, C. (2019). EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with multiple brain metastases. Annals of Oncology, 30, ii69–ii70. https://doi.org/10.1093/annonc/mdz068

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free